Prostate Cancer
Discrimination against Gay and Bisexual Patients in Prostate Cancer Treatment: Results from the Restore-2 Study.
November 26, 2024
Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer.
November 25, 2024
Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer.
November 25, 2024
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer.
November 25, 2024
PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects.
November 25, 2024
Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.
November 25, 2024
Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.
November 22, 2024
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
November 22, 2024
The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.
November 22, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.
November 22, 2024